Essex Bio-Technology Limited (1061.HK)

HKD 2.76

(0.37%)

EBITDA Summary of Essex Bio-Technology Limited

Essex Bio-Technology Limited's latest annual EBITDA in 2023 was 418.37 Million HKD , up 15.59% from previous year.
Essex Bio-Technology Limited's latest quarterly EBITDA in 2024 Q2 was 200.27 Million HKD , down 0.0% from previous quarter.
Essex Bio-Technology Limited reported an annual EBITDA of 313.53 Million HKD in 2022, down -31.71% from previous year.
Essex Bio-Technology Limited reported an annual EBITDA of 436.65 Million HKD in 2021, up 76.81% from previous year.
Essex Bio-Technology Limited reported a quarterly EBITDA of 219.54 Million HKD for 2023 Q2, down 0.0% from previous quarter.
Essex Bio-Technology Limited reported a quarterly EBITDA of N/A for 2023 FY, up 15.59% from previous quarter.

Annual EBITDA Chart of Essex Bio-Technology Limited (2023 - 2000)

Historical Annual EBITDA of Essex Bio-Technology Limited (2023 - 2000)

Year	EBITDA	EBITDA Growth
2023	418.37 Million HKD	15.59%
2022	313.53 Million HKD	-31.71%
2021	436.65 Million HKD	76.81%
2020	279.5 Million HKD	-28.6%
2019	386.14 Million HKD	30.38%
2018	299.86 Million HKD	26.99%
2017	217.35 Million HKD	23.21%
2016	177.47 Million HKD	27.3%
2015	142.91 Million HKD	30.41%
2014	109.41 Million HKD	40.98%
2013	77.73 Million HKD	47.72%
2012	52.62 Million HKD	30.89%
2011	41.32 Million HKD	21.22%
2010	33.16 Million HKD	38.54%
2009	24.56 Million HKD	-32.58%
2008	35.51 Million HKD	113.19%
2007	16.65 Million HKD	205.37%
2006	5.45 Million HKD	-4.96%
2005	5.73 Million HKD	-24.61%
2004	7.61 Million HKD	138.32%
2003	-19.86 Million HKD	-311.29%
2002	-4.82 Million HKD	-303.89%
2001	2.36 Million HKD	49.13%
2000	1.58 Million HKD	0.0%

Year	EBITDA	EBITDA Growth
2024 Q2	200.27 Million HKD	0.0%
2023 Q2	219.54 Million HKD	0.0%
2023 FY	- HKD	15.59%
2023 Q4	156.41 Million HKD	0.0%
2022 FY	- HKD	-31.71%
2022 Q2	165.31 Million HKD	0.0%
2022 Q4	149.18 Million HKD	0.0%
2021 Q2	192.18 Million HKD	0.0%
2021 FY	- HKD	76.81%
2021 Q4	243.53 Million HKD	0.0%
2020 Q2	56.96 Million HKD	0.0%
2020 Q4	177.04 Million HKD	0.0%
2020 FY	- HKD	-28.6%
2019 FY	- HKD	30.38%
2019 Q4	200.75 Million HKD	0.0%
2019 Q2	146.71 Million HKD	0.0%
2018 Q2	132.33 Million HKD	0.0%
2018 FY	- HKD	26.99%
2018 Q4	162.43 Million HKD	0.0%
2017 FY	- HKD	23.21%
2017 Q4	116.86 Million HKD	0.0%
2017 Q2	100.48 Million HKD	0.0%
2016 Q2	78.19 Million HKD	0.0%
2016 FY	- HKD	27.3%
2016 Q4	99.27 Million HKD	0.0%
2015 Q2	72.33 Million HKD	0.0%
2015 Q4	70.13 Million HKD	0.0%
2015 FY	- HKD	30.41%
2014 Q4	65.32 Million HKD	0.0%
2014 Q2	43.89 Million HKD	0.0%
2014 FY	- HKD	40.98%
2013 FY	- HKD	47.72%
2013 Q4	40.16 Million HKD	0.0%
2013 Q2	37.18 Million HKD	0.0%
2012 FY	- HKD	30.89%
2012 Q4	- HKD	0.0%
2012 Q2	- HKD	0.0%
2011 Q2	- HKD	0.0%
2011 Q4	- HKD	0.0%
2011 FY	- HKD	21.22%
2010 FY	- HKD	38.54%
2010 Q2	8.31 Million HKD	0.0%
2009 Q2	6.26 Million HKD	0.0%
2009 FY	- HKD	-32.58%
2008 FY	- HKD	113.19%
2007 FY	- HKD	205.37%
2006 FY	- HKD	-4.96%
2005 FY	- HKD	-24.61%
2004 FY	- HKD	138.32%
2003 FY	- HKD	-311.29%
2002 FY	- HKD	-303.89%
2001 FY	- HKD	49.13%
2000 FY	- HKD	0.0%

Peer EBITDA Comparison of Essex Bio-Technology Limited

Name	EBITDA	EBITDA Difference
Pak Fah Yeow International Limited	150.4 Million HKD	-178.176%
Grand Pharmaceutical Group Limited	2.96 Billion HKD	85.897%
Extrawell Pharmaceutical Holdings Limited	-129.51 Million HKD	423.021%
Wai Yuen Tong Medicine Holdings Limited	113.79 Million HKD	-267.649%
Qianhai Health Holdings Limited	-50.22 Million HKD	932.939%
Lee's Pharmaceutical Holdings Limited	109.82 Million HKD	-280.966%
Tongfang Kontafarma Holdings Limited	76.63 Million HKD	-445.949%
PuraPharm Corporation Limited	-26.16 Million HKD	1698.751%
SSY Group Limited	2.11 Billion HKD	80.214%
JBM (Healthcare) Limited	204.39 Million HKD	-104.695%
Jacobson Pharma Corporation Limited	429.92 Million HKD	2.685%
China Resources Pharmaceutical Group Limited	15.43 Billion HKD	97.289%